Diversified Trust Co Sells 2,426 Shares of Cencora, Inc. $COR

Diversified Trust Co trimmed its holdings in Cencora, Inc. (NYSE:COR) by 5.4% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 42,796 shares of the company’s stock after selling 2,426 shares during the quarter. Diversified Trust Co’s holdings in Cencora were worth $13,375,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. State of Wyoming lifted its position in shares of Cencora by 15.2% during the first quarter. State of Wyoming now owns 742 shares of the company’s stock worth $206,000 after purchasing an additional 98 shares in the last quarter. MAI Capital Management increased its stake in shares of Cencora by 18.3% in the 1st quarter. MAI Capital Management now owns 5,467 shares of the company’s stock valued at $1,520,000 after buying an additional 846 shares during the period. Paloma Partners Management Co lifted its stake in shares of Cencora by 52.4% during the first quarter. Paloma Partners Management Co now owns 3,480 shares of the company’s stock valued at $968,000 after acquiring an additional 1,197 shares during the period. First Manhattan CO. LLC. lifted its stake in shares of Cencora by 4.0% during the first quarter. First Manhattan CO. LLC. now owns 276,478 shares of the company’s stock valued at $76,886,000 after acquiring an additional 10,695 shares during the period. Finally, PDT Partners LLC boosted its holdings in Cencora by 131.3% in the first quarter. PDT Partners LLC now owns 24,132 shares of the company’s stock valued at $6,711,000 after acquiring an additional 13,698 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on COR. Wells Fargo & Company raised their target price on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. JPMorgan Chase & Co. increased their price objective on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Evercore ISI set a $400.00 target price on shares of Cencora and gave the stock an “outperform” rating in a report on Thursday, November 6th. Barclays started coverage on Cencora in a research note on Monday, December 8th. They issued an “overweight” rating and a $400.00 price target on the stock. Finally, Mizuho raised their price target on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $373.25.

Insiders Place Their Bets

In other Cencora news, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the sale, the executive vice president directly owned 18,796 shares in the company, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $343.45, for a total transaction of $1,750,221.20. Following the completion of the transaction, the chief executive officer owned 68,059 shares of the company’s stock, valued at $23,374,863.55. This trade represents a 6.97% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 20,317 shares of company stock worth $7,009,260. Company insiders own 10.80% of the company’s stock.

Cencora Trading Down 0.3%

Shares of NYSE COR opened at $340.08 on Tuesday. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32. Cencora, Inc. has a twelve month low of $223.92 and a twelve month high of $377.54. The company’s fifty day moving average is $348.91 and its 200-day moving average is $315.59. The stock has a market cap of $65.97 billion, a price-to-earnings ratio of 42.78, a P/E/G ratio of 1.62 and a beta of 0.63.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The business had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. During the same quarter last year, the business posted $3.34 EPS. The firm’s revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Equities research analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.